| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Neurogene Inc.$39.63
-3.21 (-7.49%)
D 33Pipeline Score Richly Valued Biotech · Clinical
Market Cap
437.87 M
EPS
-5.02
P/E Ratio
-
Value Trade
2.30 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
25.15 M
Operating CF
-26.12 M
Total Assets
263.14 M
Total Liabilities
25.36 M
Equity
237.78 M
D/E Ratio
12,345
-9.56 %
Week
2.9 %
1 Month
50.76 %
3 Month
36.64 %
6 Month
-86.98 %
5 Year
-88.26 %
All Time
Cash Data
Cash Position
243.18 M
Monthly Burn
8.71 M
Runway
25.9 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
290.58 K
52 Week Range
14.65 - 37.27
% held by Insiders
20.67 %
% held by Institutions
96.68 %
Enterprise Value
203.82 M
Total Shares
15.48 M
Short %
34.42 %
Float Shares
9.74 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Neurogene Inc.
251Total events
1Upcoming
55Tier-1 (high impact)
2014 – 2028Coverage
Upcoming catalysts 1
Event history 250
Jun 29, 2026
▲Full ResultsNGN-401Clinical Data
Positive long-term clinical data reported from Phase 1/2 trial of NGN-401
Rett syndromesource ↗
Jun 8, 2026
▲Enrollment CompleteNGN-401Trial
Successful completion of dosing in Embolden registrational trial of NGN-401 for Rett Syndrome
Rett Syndromesource ↗
Jun 2026
◆Oral PresentationNGN-401Presentation
Presentation of additional interim Phase 1/2 clinical data
Rett syndromesource ↗
Jun 2026
◆Interim AnalysisNGN-401Trial
Additional interim Phase 1/2 data expected mid-2026
Rett syndromesource ↗
May 12, 2026
◆Oral PresentationPresentation
Data presentation at ASGCT meeting supporting ICV delivery method
CNS-targeted gene therapysource ↗
May 12, 2026
◆Poster PresentationNGN-401Presentation
Poster presentation on ICV delivery rationale for NGN-401 at ASGCT 2026
Rett syndromesource ↗
May 12, 2026
▲Enrollment MilestoneNGN-401Trial
Dosed ~90% of participants in Embolden registrational trial
Rett syndromesource ↗
May 12, 2026
●Oral PresentationNGN-401Presentation
Presentation at ASGCT Meeting highlighted therapeutic rationale for ICV delivery in CNS-targeted gene therapy, including NGN-401
Rett syndromesource ↗
Drug Pipeline Intelligence
D33
Pipeline Score $19M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 42%
Micro Cap (rank 530 of 912)
Percentile RankNeurogene Inc. faces pipeline headwinds (33/100), with $47M risk-adjusted pipeline value, led by NL-201 in Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NL-201 Small molecule | Solid Tumor | Phase 1 | NCT04659629 | 5% | $47M | COMPLETED | 59 | - | - | Aug 15, 2024 | - | Oct 1, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
NGN-401 Breakthrough | Rett syndrome | Phase 1/2 | 2026-04-28 | safety profile at the 1E15 vg dose that supports continued advancement Read More | Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy Read More | |
NGN-401 Breakthrough | Rett syndrome | Phase 1/2 | 2026-04-28 | safety profile at the 1E15 vg dose that supports continued advancement Read More | Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy Read More | |
NGN-401 Breakthrough | Rett syndrome | Phase 1/2 | 2026-04-28 | safety profile at the 1E15 vg dose that supports continued advancement Read More | Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NGNE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NGNE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NGNE▲ +7.7%on this news
Neurogene Inc. Announces Pricing of $125 Million Public Offering
Neurogene Inc. has announced the pricing of a public offering amounting to $125 million. This move is part of the company's strategy to raise capital, although further details on the intended use of the funds were not provided. The announcement reflects the company's ongoing efforts to strengthen its financial position.
Read more →NGNE▲ +7.7%on this newsshared move
Neurogene Inc. Announces Proposed Public Offering
Neurogene Inc. has announced a proposed public offering. Details regarding the offering, including the number of shares and pricing, have not been disclosed in the article. The announcement suggests that the company is looking to raise capital, but further information is needed to assess the potential impact.
Read more →NGNENeurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Neurogene has announced positive long-term clinical data from its Phase 1/2 trial of NGN-401, a gene therapy aimed at treating Rett Syndrome. The results suggest that NGN-401 may be effective in addressing the symptoms associated with this condition. This development marks a significant step forward in the treatment options available for patients with Rett Syndrome.
Read more →NGNE▲ +8%on this news
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
Neurogene has announced the successful completion of dosing in its Embolden™ registrational trial for NGN-401, aimed at treating Rett Syndrome. This milestone marks a significant step forward in developing therapies for this rare condition. The trial's progress is expected to enhance treatment options for patients affected by Rett Syndrome.
Read more →NGNENeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
Neurogene Inc. announced the approval of non-qualified stock options for two new employees as part of its 2025 Inducement Plan. The grants, totaling 17,045 shares, are designed to incentivize new hires in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, promoting long-term commitment to the company.
Read more →NGNENeurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
Neurogene presented data at the ASGCT meeting that supports the therapeutic rationale for using intraventricular (ICV) delivery methods in CNS-targeted gene therapy. The findings aim to enhance understanding of gene therapy applications in treating central nervous system disorders. Further details on the data and its implications were discussed during the event.
Read more →NGNENeurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene has released its financial results for the first quarter of 2026. The report includes recent updates regarding the company's operations and financial performance. However, specific details about the financial results or operational highlights were not provided in the article.
Read more →NGNENeurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
Neurogene Inc. announced an upcoming poster presentation at the ASGCT Annual Meeting, focusing on the benefits of intracerebroventricular (ICV) delivery for CNS-targeted gene therapy, specifically for Rett syndrome. The presentation will showcase preclinical data indicating superior biodistribution of NGN-401 via ICV compared to intrathecal-lumbar administration. Interim results from ongoing trials suggest positive safety and efficacy outcomes.
Read more →NGNENeurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
Neurogene has announced the appointment of Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to its Board of Directors. These appointments are expected to enhance the company's leadership and strategic direction. The new executives bring valuable experience that may contribute to Neurogene's growth and success in the biopharma sector.
Read more →NGNENeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene has announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). This move is part of their strategy to enhance employee retention and attract talent. The specifics of the grants were not detailed in the announcement.
Read more →NGNE▲ +8%on this news
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
Neurogene has reported its financial results for the full year 2025, highlighting key updates. The report includes insights into the company's performance and strategic direction. However, specific details on financial metrics or developments were not provided in the article.
Read more →NGNE▲ +8.7%on this news
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 3, 2026
Neurogene Inc. has announced the approval of non-qualified stock options for four new employees as part of its 2025 Inducement Plan. This grant, totaling 32,450 shares, is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent. The options will vest over four years, aligning with the company's growth strategy in developing genetic medicines for neurological diseases.
Read more →NGNE▲ +19.4%on this newsshared move
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
Neurogene Inc. has received FDA Breakthrough Therapy designation for NGN-401, a gene therapy aimed at treating Rett syndrome. This designation is based on interim Phase 1/2 trial data showing significant functional improvements in patients. The company plans to complete dosing in its registrational trial by the second quarter of 2026 and present more data in mid-2026.
Read more →NGNENeurogene to Participate in Upcoming Investor Conferences
Neurogene Inc. will participate in several upcoming investor conferences, including the Guggenheim Emerging Outlook: Biotech Summit, TD Cowen 46th Annual Health Care Conference, and the Leerink Global Healthcare Conference. The management will engage in fireside chats and investor meetings, highlighting their commitment to advancing genetic medicines for rare neurological diseases. The company emphasizes its innovative approaches in gene therapy and has established a state-of-the-art manufacturing facility.
Read more →NGNENeurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 4, 2026
Neurogene Inc. has announced the approval of an Inducement Grant for a new employee, involving non-qualified stock options for 2,820 shares. This grant, effective February 2, 2026, is part of the company's 2025 Inducement Plan and complies with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, contingent on continued employment.
Read more →NGNE▼ -8.6%on this news
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Neurogene Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 14 at 7:30 a.m. PT. The management will present an overview of the company and engage in investor meetings. Neurogene focuses on developing genetic medicines for rare neurological diseases and has established a state-of-the-art manufacturing facility in Houston.
Read more →NGNEcomparable to the earnings per share information for the post-merger period, the earnings per share information is being presented separately for these periods. See Note 3, Net Income (Loss) Per share , for additional in
Neurogene Inc. reported its financial results for Q4 and full year 2023, demonstrating a strong financial position with cash reserves extending into the second half of 2026. The company is progressing in its Phase 1/2 trial for NGN-401, a gene therapy for Rett syndrome, expanding the study to include higher dose cohorts. Interim data from this trial is expected in 4Q 2024, while also advancing its NGN-101 program for CLN5 Batten disease. Despite some increases in administrative costs tied to their recent reverse merger, the company continues to show optimism in its therapeutic development and pipeline.
Read more →NGNE▲ +20.5%on this news
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial Ongoing Phase 1/2 clinical trial for NGN-401 to include additional patients in Cohort 1 and a dose-es
Neurogene announced the expansion of its Phase 1/2 gene therapy clinical trial for NGN-401, targeting Rett syndrome in pediatric patients. Modifications will allow for more rapid patient enrollment and the addition of a high dose cohort. The company has successfully dosed a third patient and expects to complete Cohort 1 enrollment by late 2024. The updated trial design aims to enhance data collection for future regulatory discussions.
Read more →NGNEto the Company s Current Report on Form 8-K filed with the SEC on
Neurogene has announced significant progress in its clinical trials, particularly for NGN-401, a gene therapy for Rett syndrome, which is now cleared for dosing further pediatric patients. The company has cleared regulatory hurdles both in the U.S. and the UK, strengthening its position for global trials. With a solid financial foundation of around $200 million, Neurogene is well-positioned to continue its research and development efforts into 2024. The firm anticipates interim clinical results from its ongoing trials by the end of 2024.
Read more →NGNENeurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome Two pediatric patients with Rett syndrome dosed in the United States with NGN-401, Neurogene
Neurogene has initiated a Phase 1/2 clinical trial for its gene therapy NGN-401, dosing the first two pediatric patients suffering from Rett syndrome. The treatment, designed using proprietary EXACT gene regulation technology, has shown a favorable safety profile with no serious adverse events thus far. A third patient is expected to be dosed in Q1 2024, and interim efficacy data is anticipated in Q4 2024. This groundbreaking therapy aims to address significant unmet medical needs in this rare neurological disorder.
Read more →NGNENEUROGENE AND NEOLEUKIN ANNOUNCE DEFINITIVE MERGER AGREEMENT Proposed merger to create Nasdaq-listed biotech company focused on advancing Neurogene s differentiated portfolio of genetic medicines for complex neurological
Neurogene Inc. and Neoleukin Therapeutics have announced a definitive merger agreement to form a new biotechnology company focused on genetic medicines for rare neurological diseases. This all-stock transaction aims to leverage Neurogene's differentiated portfolio, including its NGN-401 product for Rett syndrome. The merger, which is pending stockholder approval, is designed to enhance the combined company's ability to advance its clinical pipeline and support its internal manufacturing capabilities. Following the merger, the company expects to trade on the Nasdaq Capital Market under the ticker symbol NGNE.
Read more →NGNEDocument EX-99.1 Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition
Neoleukin Therapeutics has announced a strategic update involving a comprehensive review of alternatives aimed at maximizing shareholder value. This process, facilitated by SVB Securities, may lead to potential sales or divestitures. In conjunction, the company will restructure by significantly reducing its workforce by about 70% and will see the departure of its CEO, Jonathan Drachman. These steps are viewed as necessary in the current challenging capital markets environment, although they indicate substantial operational changes.
Read more →NGNEDocument EX-99.1 Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update - Development of NL-201 to be discontinued for strategic reasons - - Company to focus on next-generation de novo
Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update -Development of NL-201 to be discontinued for strategic reasons - -Company to focus on next-generation de novo proteins and core technology - -Company restructuring to extend cash runway
Read more →NGNEDocument EX-99.1 Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results Provides Corporate Update - Company to Host Conference Call Today
Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results Provides Corporate Update -Company to Host Conference Call Today, August 9, 2022, at 1 30 p.m. Pacific 4 30 p.m. Eastern - SEATTLE, Washington, August 9, 2022 - Neoleukin Therapeutics, Inc., "Neoleukin" (NAS
Read more →NGNEDocument Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022 SEATTLE, Washington, July 27, 2022 - Neoleukin Therapeutics, Inc., Neoleukin" (NASDAQ NLTX), today announced it will report second quarter 2022 financial results on
Read more →NGNEDocument Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update
Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update SEATTLE, Washington, May 9, 2022 - Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo prot
Read more →NGNEDocument Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update - Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second hal
Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update -Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 - -$142.5 million in cash and cash equivalents expected to
Read more →NGNECorporate Presentation November 2021 Forward Looking Statements Certain of the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin's business,
Forward Looking Statements Certain of the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin's business, strategy, future operations, advancement of its product candidates and product pipeline, clinic
Read more →NGNEDocument Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update - NL-201 Phase 1 solid tumor trial interim data anticipated in 2022 - - Upcoming presentations at ACR, SITC, and ASH to
Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update -NL-201 Phase 1 solid tumor trial interim data anticipated in 2022 - -Upcoming presentations at ACR, SITC, and ASH to highlight preclinical data - -Planning to initiate a Phase 1 trial i
Read more →NGNEDisclosures Hui-Ling Yen, PhD: received donation from Saiba AG and has performed contract research for Neoleukin Therapeutics, Inc. Wen Su, PhD: has no conflict of interest to declare. Gon alo Bernardes, PhD: consultant
Antiviral NL-CVX1 efficiently blocks infection by SARS-CoV-2 viral variants of concern (VOC) Maria Rebelo, PhD Gon alo Bernardes Lab Instituto de Medicina Molecular Lisboa, Portugal mariarebelo@medicina.ulisboa.pt Exhibit 99.1 Disclosures Hui-Ling Yen, PhD: received donation fro
Read more →NGNEDocument Neoleukin Therapeutics Announces Second Quarter 2021 Financial Results Provides Corporate Update
Neoleukin Therapeutics Announces Second Quarter 2021 Financial Results Provides Corporate Update SEATTLE, Washington, August 5, 2021 - Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de
Read more →NGNEForward Looking Statements Certain of the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin's business, strategy, future operations, advance
June 2, 2021 Exhibit 99.1 Forward Looking Statements Certain of the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin's business, strategy, future operations, advancement of its product candidates a
Read more →NGNENeoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update - Entered clinical development with first patient dosed in Phase 1 Trial of NL-201 - - Appointed Priti Patel, M.D., as Chief Medi
Neoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update - Entered clinical development with first patient dosed in Phase 1 Trial of NL-201 - - Appointed Priti Patel, M.D., as Chief Medical Officer - - Cash and cash equivalents of $178.4 milli
Read more →NGNENeoleukin Therapeutics Announces Year End 2020 Financial Results - Anticipating first patient for NL-201 Phase 1 Trial in 1H21 - - Cash and cash equivalents of $192.6 million expected to fund operations into 2023 - - Com
Neoleukin Therapeutics Announces Year End 2020 Financial Results - Anticipating first patient for NL-201 Phase 1 Trial in 1H21 - - Cash and cash equivalents of $192.6 million expected to fund operations into 2023 - - Company to host Conference Call Today, March 25, 2021 at 1 3
Read more →NGNENeoleukin Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Update -NL-201 IND submission anticipated by year end 2020- -Clinical Trial Notification application submitted in Australia- -Ended 3 rd
Neoleukin Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Update -NL-201 IND submission anticipated by year end 2020- -Clinical Trial Notification application submitted in Australia- -Ended 3rd quarter with $201.2 million in cash and cash equivalents-
Read more →NGNENeoleukin Therapeutics Announces Second Quarter 2020 Financial Results & Provides Corporate Update - NL-201 IND submission anticipated during fourth quarter of 2020 - - Recent financing raises $71.4M in net proceeds to e
Neoleukin Therapeutics Announces Second Quarter 2020 Financial Results & Provides Corporate Update - NL-201 IND submission anticipated during fourth quarter of 2020 - - Recent financing raises $71.4M in net proceeds to enable broad NL-201 clinical plan and product pipeline deve
Read more →NGNENeoleukin Therapeutics Announces Pricing of $76.2 Million Public Offering SEATTLE
Neoleukin Therapeutics Announces Pricing of $76.2 Million Public Offering SEATTLE, July 2, 2020 (GLOBE NEWSWIRE) Neoleukin Therapeutics, Inc. ( Neoleukin ) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein thera
Read more →NGNENeoleukin Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update - IND submission for NL-201 anticipated by end of 2020 - - Three abstracts to be presented at AACR-II
Neoleukin Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update - IND submission for NL-201 anticipated by end of 2020 - - Three abstracts to be presented at AACR-II - SEATTLE, Washington, May 6, 2020 - Neoleukin Therapeutics, Inc. ("Neoleuki
Read more →NGNENeoleukin Therapeutics Announces Year End Financial Results - NL-201 IND Submission Expected by End of 2020 - - Company to host Conference Call Today
Neoleukin Therapeutics Announces Year End Financial Results - NL-201 IND Submission Expected by End of 2020 - - Company to host Conference Call Today, March 12, 2020 at 1:30 p.m. Pacific / 4:30 p.m. Eastern - Washington, March 12, 2020 Neoleukin Therapeutics, Inc. Neoleukin (
Read more →NGNEDe novo proteins for immunotherapy January 2020 Forward Looking Statements Certain of the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin
De novo proteins for immunotherapy January 2020 Forward Looking Statements Certain of the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin s business, strategy, future operations, advancement of it
Read more →NGNENeoleukin Therapeutics Announces Pricing of $75.0 Million Public Offering
Neoleukin Therapeutics Announces Pricing of $75.0 Million Public Offering SEATTLE, Washington, December 17, 2019 (GLOBE NEWSWIRE) Neoleukin Therapeutics, Inc. ( Neoleukin ) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de n
Read more →NGNENeoleukin Therapeutics Announces Corporate Update and Third Quarter 2019 Financial Results
Neoleukin Therapeutics Announces Corporate Update and Third Quarter 2019 Financial Results SEATTLE, Washington, November 13, 2019 Neoleukin Therapeutics, Inc. Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo p
Read more →NGNEAquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement Combined company capitalized with approximately $65M to develop novel immunotherapies Sophisticated computational platform enables new class of
Aquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement VANCOUVER, British Columbia and SEATTLE, Washington, August 6, 2019 Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ:AQXP) and Neoleukin Therapeutics, Inc. ( Neoleukin ), a privately held biopharmace
Read more →NGNEDESCRIPTION OF NEOLEUKIN S BUSINESS Overview Following the closing of our acquisition of Neoleukin Therapeutics, Inc. in accordance with the terms of the Agreement and Plan of Merger dated
DESCRIPTION OF NEOLEUKIN S BUSINESS the closing of our acquisition of Neoleukin Therapeutics, Inc. in accordance with the terms of the Agreement and Plan of Merger dated August 5, 2019 by and among us, Neoleukin Therapeutics, Inc. and Apollo Sub, Inc., or the Merger, we are a b
Read more →NGNEAquinox Pharmaceuticals Announces Third Quarter 2018 Financial Results VANCOUVER, British Columbia
Aquinox Pharmaceuticals Announces Third Quarter 2018 VANCOUVER, British Columbia, November 7, 2018 Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ:AQXP), a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and bl
Read more →NGNEAquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results VANCOUVER, British Columbia
Aquinox Pharmaceuticals Announces Second Quarter 2018 Columbia, August 8, 2018 Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ:AQXP), a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today p
Read more →NGNEAquinox Announces Topline Results of Phase 3 LEADERSHIP 301 Clinical Trial in Interstitial Cystitis/Bladder Pain Syndrome VANCOUVER, British Columbia
Aquinox Announces Topline Results of Phase 3 LEADERSHIP 301 Clinical Trial in Interstitial Cystitis/Bladder Pain Syndrome VANCOUVER, British Columbia, June 27, 2018 Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ:AQXP) today announced that the Phase 3 LEADERSHIP 301 clinical
Read more →NGNEAquinox Pharmaceuticals Announces Initiation of ProShip Phase 2 Proof-of-Concept Clinical Trial Investigating Rosiptor in CP/CPPS -Trial Will Enroll Approximately 100 Male Subjects in the US and Canada- VANCOUVER, Britis
Aquinox Pharmaceuticals Announces Initiation of ProShip Phase 2 Proof-of-Concept Clinical Trial Investigating Rosiptor in -Trial Will Enroll Approximately 100 Male Subjects in the US and Canada- VANCOUVER, British Columbia, June 11, 2018 Aquinox Pharmaceuticals, Inc. ( Aquinox
Read more →NGNEAquinox Pharmaceuticals Announces First Quarter 2018 Financial Results VANCOUVER, British Columbia
Aquinox Pharmaceuticals Announces First Quarter 2018 Financial Results VANCOUVER, British Columbia, May 8, 2018 Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammati
Read more →NGNEAquinox Pharmaceuticals Announces Year End 2017 Financial Results VANCOUVER, British Columbia
Aquinox Pharmaceuticals Announces Year End 2017 Financial Results VANCOUVER, British Columbia, March 12, 2018 Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation,
Read more →NGNEAquinox R&D Day
Aquinox R&D Day February 9, 2018 David Main President & CEO Forward Looking Statements/ Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial risks and uncertainties. All statements other than statements o
Read more →NGNEForward Looking Statements/ Safe Harbor This presentation and the accompanying oral commentary contain "forward-looking" statements that involve substantial risks and uncertainties. All statements other than statements o
Targeted Therapeutics for Inflammatory Disease January 2018 Exhibit 99.1 Forward Looking Statements/ Safe Harbor This presentation and the accompanying oral commentary contain "forward-looking" statements that involve substantial risks and uncertainties. All statements other t
Read more →NGNEAquinox Pharmaceuticals Announces Third Quarter 2017 Financial Results Vancouver, British Columbia
Aquinox Pharmaceuticals Announces Third Quarter 2017 Financial Results Vancouver, British Columbia November 8, 2017 - (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeut
Read more →NGNEAquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results - Conference call update today at 8:30AM ET - Vancouver, British Columbia
Aquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results - Conference call update today at 8:30AM ET - Vancouver, British Columbia August 8, 2017 - (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-stage pharmaceutical company
Read more →NGNEAquinox Pharmaceuticals Announces First Quarter 2017 Financial Results Vancouver, British Columbia
Aquinox Pharmaceuticals Announces First Quarter 2017 Financial Results Vancouver, British Columbia May 9, 2017 - (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics i
Read more →NGNEAquinox Pharmaceuticals Announces Year End 2016 Financial Results - Conference call update today at 4:30 PM ET - Vancouver, British Columbia
Aquinox Pharmaceuticals Announces Year End 2016 Financial Results - Conference call update today at 4:30 PM ET - Vancouver, British Columbia March 9, 2017 (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-stage pharmaceutical company discove
Read more →NGNEAquinox Pharmaceuticals Announces Third Quarter 2016 Financial Results Vancouver, British Columbia
Aquinox Pharmaceuticals Announces Third Quarter 2016 Financial Results Vancouver, British Columbia November 9, 2016 - (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeut
Read more →NGNEAquinox Pharmaceuticals Initiates Patient Dosing in LEADERSHIP 301 Phase 3 Clinical Trial of AQX-1125 in Interstitial Cystitis/Bladder Pain Syndrome Vancouver, British Columbia
Aquinox Pharmaceuticals Initiates Patient Dosing in LEADERSHIP 301 Phase 3 Clinical Trial of AQX-1125 in Interstitial Cystitis/Bladder Pain Vancouver, British Columbia September 6, 2016 - (GLOBE NEWSWIRE) - Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-s
Read more →NGNEAquinox Pharmaceuticals Announces Second Quarter 2016 Financial Results - Conference call update today at 4:30PM ET - Vancouver, British Columbia
Aquinox Pharmaceuticals Announces Second Quarter 2016 Financial Results - Conference call update today at 4:30PM ET - Vancouver, British Columbia August 4, 2016 - (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-stage pharmaceutical company
Read more →NGNEAquinox Pharmaceuticals Announces First Quarter 2016 Financial Results Vancouver, British Columbia
Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results Vancouver, British Columbia May 10, 2016 (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in
Read more →NGNEAquinox Pharmaceuticals Announces Year End 2015 Financial Results Advancing to first Phase 3 trial for AQX-1125 in IC/BPS Host conference call update today at 4:30PM ET Vancouver, British Columbia
Aquinox Pharmaceuticals Announces Year End 2015 Financial Results Advancing to first Phase 3 trial for AQX-1125 in IC/BPS Host conference call update today at 4:30PM ET Vancouver, British Columbia March 14, 2016 - (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NAS
Read more →NGNEAquinox Announces Update on Development Program for AQX-1125 Following Meeting with FDA Vancouver, British Columbia
Aquinox Announces Update on Development Program for AQX-1125 Following Meeting with FDA Vancouver, British Columbia January 11, 2016 - (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-stage pharmaceutical company discovering and developing
Read more →NGNEAquinox Pharmaceuticals Reports Third Quarter 2015 Financial Results Vancouver, British Columbia
Aquinox Pharmaceuticals Reports Third Quarter 2015 Financial Results Vancouver, British Columbia November 10, 2015 (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics
Read more →NGNEAquinox Pharmaceuticals Announces Results from Phase 2 KINSHIP Trial with AQX-1125 in Patients with Atopic Dermatitis Vancouver, British Columbia
Aquinox Pharmaceuticals Announces Results from Phase 2 KINSHIP Trial with AQX-1125 in Patients with Atopic Vancouver, British Columbia November 2, 2015 (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (Nasdaq: AQXP), a clinical-stage pharmaceutical company discovering
Read more →NGNETargeted Therapeutics for Inflammatory Disease R&D Day
Targeted Therapeutics for Inflammatory Disease R&D Day October 7, 2015 Forward Looking Statements / Safe Harbor presentation and the accompanying oral commentary contain forward-looking statements that involve substantial risks and uncertainties. All statements other than sta
Read more →NGNEAquinox Presents at 2015 International Society for the Study of BPS Conference - Responder analyses reinforce magnitude of benefit with AQX-1125 - Vancouver, British Columbia
Aquinox Presents at 2015 International Society for the Study of BPS Conference - Responder analyses reinforce magnitude of benefit with AQX-1125 - Vancouver, British Columbia September 18, 2015 (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinic
Read more →NGNEAquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update AQX-1125 in BPS/IC Aquinox
Aquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update AQX-1125 in BPS/IC Forward Looking Statements / Safe Harbor presentation and the accompanying oral commentary contain forward-looking statements that involve substantial risks and uncertainties. All stateme
Read more →NGNEAquinox Pharmaceuticals Announces Positive Results from Secondary Endpoints from Phase 2 LEADERSHIP Trial in BPS/IC and Reports Second Quarter 2015 Financial Results Vancouver, British Columbia
Aquinox Pharmaceuticals Announces Positive Results from Secondary Endpoints from Phase 2 LEADERSHIP Trial in BPS/IC and Reports Second Quarter 2015 Financial Results Vancouver, British Columbia - August 6, 2015 - (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASD
Read more →NGNEAquinox Pharmaceuticals Announces Results from FLAGSHIP Trial with AQX-1125 in Chronic Obstructive Pulmonary Disease Patients with Frequent Exacerbations Vancouver, British Columbia
Aquinox Pharmaceuticals Announces Results from FLAGSHIP Trial with AQX-1125 in Chronic Obstructive Pulmonary Disease Patients with Frequent Exacerbations Vancouver, British Columbia July 9, 2015 (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (Nasdaq: AQXP), a clin
Read more →NGNEAquinox Pharmaceuticals Announces Results from LEADERSHIP Trial with AQX-1125 in Patients with Bladder Pain Syndrome/Interstitial Cystitis Vancouver, British Columbia
Aquinox Pharmaceuticals Announces Results from LEADERSHIP Trial with AQX-1125 in Patients with Bladder Pain Syndrome/Interstitial Cystitis Vancouver, British Columbia June 25, 2015 (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (Nasdaq: AQXP), a clinical-stage phar
Read more →NGNEAquinox Pharmaceuticals Announces First Quarter 2015 Financial Results Vancouver, British Columbia
Aquinox Pharmaceuticals Announces First Quarter 2015 Financial Results Vancouver, British Columbia - May 12, 2015 - (GLOBE NEWSWIRE) - Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeut
Read more →NGNEAquinox Pharmaceuticals Completes Enrollment in the Phase 2 KINSHIP Trial of AQX-1125 in Atopic Dermatitis Vancouver, British Columbia
Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 KINSHIP Trial of AQX-1125 in Atopic Dermatitis Vancouver, British Columbia May 4, 2015 (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-stage pharmaceutical company discovering and
Read more →NGNEAquinox Pharmaceuticals Announces Year End 2014 Financial Results Vancouver, British Columbia
Aquinox Pharmaceuticals Announces Year End 2014 Financial Results Vancouver, British Columbia March 16, 2015 (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in di
Read more →NGNEAquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis Vancouver, British Columbia
Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis Vancouver, British Columbia March 2, 2015 - (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-stage pharma
Read more →NGNEAquinox Pharmaceuticals Completes Enrollment in the Phase 2 FLAGSHIP Trial of AQX-1125 in Chronic Obstructive Pulmonary Disease Exacerbations Vancouver, British Columbia
Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 FLAGSHIP Trial of AQX-1125 in Chronic Obstructive Pulmonary Disease Vancouver, British Columbia February 2, 2015 (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-stage pharmaceutica
Read more →NGNEAquinox Pharmaceuticals Initiates Patient Dosing in the Phase 2 Clinical Trial of AQX-1125 in Atopic Dermatitis VANCOUVER, British Columbia
Aquinox Pharmaceuticals Initiates Patient Dosing in the Phase 2 Clinical Trial of AQX-1125 in Atopic Dermatitis VANCOUVER, British Columbia, December 30, 2014 (GLOBE NEWSWIRE) Aquinox Pharmaceuticals, Inc. ( Aquinox ) (Nasdaq: AQXP), a clinical-stage pharmaceutical company disc
Read more →NGNEAquinox Pharmaceuticals Announces Appointment of Mr. David C. Mitchell as Vice President, Global Regulatory Affairs & Quality Assurance. VANCOUVER, British Columbia
Aquinox Pharmaceuticals Announces Appointment of Mr. David C. Mitchell as Vice President, Global Regulatory Affairs & Quality Assurance. VANCOUVER, British Columbia December 9, 2014 Aquinox Pharmaceuticals, Inc. ( Aquinox ) (Nasdaq: AQXP), a clinical-stage pharmaceutical compan
Read more →NGNEAquinox Pharmaceuticals Announces Third Quarter 2014 Financial Results Vancouver, British Columbia
Aquinox Pharmaceuticals Announces Third Quarter 2014 Financial Results Vancouver, British Columbia - November 4, 2014 - Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics for inflam
Read more →NGNEAquinox Pharmaceuticals Announces Second Quarter 2014 Financial Results Conference Call at 4:45 pm Eastern Time Today Vancouver, British Columbia
Aquinox Pharmaceuticals Announces Second Quarter 2014 Financial Results Conference Call at 4:45 pm Eastern Time Today Vancouver, British Columbia August 11, 2014 Aquinox Pharmaceuticals, Inc. ( Aquinox ) (NASDAQ: AQXP), a clinical-stage pharmaceutical company discovering and d
Read more →NGNEAquinox Pharmaceuticals Announces First Quarter 2014 Financial Results Vancouver, British Columbia
Aquinox Pharmaceuticals Announces First Quarter 2014 Financial Results Vancouver, British Columbia May 13, 2014 Aquinox Pharmaceuticals, Inc. ( Aquinox , NASDAQ: AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory dis
Read more →Competitive Position
How NGNE ranks across every disease it competes inCompetitive Position is a premium feature
See how NGNE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial